FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Metastatic Breast Cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Genetic testing among people with cancer can find mutations that may affect treatment and prevention
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People diagnosed with cancer who have not yet had genetic testing
Despite national guidelines recommending genetic testing, less than 10 percent of eligible patients had genetic testing within two years after their cancer diagnosis. Among those who had testing, 10-30 percent had an inherited mutation that could affect their medical care. (Posted 3/15/2024)
Read MoreRelevance: Medium
Update : News from the FDA– new breast cancer treatment, thermography warning and implant screening updates
Relevance: Medium
Most relevant for: People with HR-positive and HER2-negative metastatic breast cancer. People with silicone breast implants. People considering thermography screening
This XRAY review is a summary of FDA breast cancer updates from July to December 2023. This includes a new drug approval and two consumer updates. (Posted 2/21/24)
Read MoreUpdate : New drug combination for the second treatment of some HR-positive advanced breast cancers
Most relevant for: People with hormone receptor (HR)-positive or HER2-negative breast cancer that has spread outside the breast tissue.
The FDA approved Truqap plus Faslodex for the treatment of metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer that returned or worsened after treatment with hormone therapy. The approval is for treating cancers in people whose tumors had a mutation in one of three genes. For people with one of these mutations, Truqap improved the time until their cancer came back or got worse. (Posted 2/9/24)
Este artículo está disponible en español.
Read MoreRelevance: High
Quality of Writing: Medium-High
Article : Genetic testing and the future of medicine
Relevance: High
Quality of Writing: Medium-High
Most relevant for: People interested in genetic testing.
An article published in Katie Couric Media discusses genetic testing and how it can impact health. The author talked with Dr. Robert Steiner, a doctor who specializes in genetics. He talked about genetic testing and how the results can affect health and change lives. (Posted 9/28/23)
Este artículo está disponible en español.
Read MoreRelevance: Medium-Low
Quality of Writing: Medium
Research Timeline: Animal Studies
View Related Clinical TrialsArticle : Promising drug for cancer treatment begins clinical trials
Relevance: Medium-Low
Quality of Writing: Medium
Research Timeline: Animal Studies
View Related Clinical TrialsMost relevant for: People with solid tumors.
Researchers at City of Hope are testing a new type of cancer treatment drug. When tested in animals and cells taken from human cancers, this new drug prevented the growth of many types of cancer. Initial clinical trials in people have just started. (Posted 9/7/23)
Este artículo está disponible en español.
Read MoreTopic : Sex and intimacy after breast cancer
Most relevant for: People with breast cancer or metastatic breast cancer in sexual or intimate relationships and their partners
A breast cancer diagnosis and treatment can affect relationships with romantic partners. This review highlights two studies that looked at how people with breast cancer and their partners are affected, how they cope, how best to communicate with each other and how to talk with healthcare providers about concerns related to cancer and sexuality. (Posted 8/8/23)
Este artículo está disponible en español.
Read MoreRelevance: Medium
Topic : Impact of new laws on cancer treatment during pregnancy
Relevance: Medium
Most relevant for: People who have cancer who are pregnant
The U.S. Supreme Court ruled in 2022 that abortion is no longer a protected right under the Constitution. This landmark decision leaves regulation of abortion to the states. Cancer treatment during pregnancy may now be impacted in states that have abortion bans or limitations. (Posted 5/31/23)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Breast cancer outcomes improved with CDK4/6 inhibitor treatment
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with HR-positive HER2-negative advanced breast cancer
A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : New oral drug treatment for some advanced breast cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with HR-positive, HER2-negative advanced breast cancer
The FDA has approved a new oral drug called Oserdu for the treatment of HR-positive, HER2-negative advanced breast cancer. A blood test was also approved to help doctors identify patients who would benefit most from this new treatment. (Posted 3/20/23)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Trodelvy benefits people with advanced hormone-positive metastatic breast cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with ER/PR-positive, HER2-negative metastatic breast cancer
The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)
Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.
Este artículo está disponible en español.
Read MoreSearch XRAY studies and Articles
This Portal Sponsored By: